Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia

Neuroscience

Volumn 281, Issue , 2014, Pages 269-281

  Briyal, S ^a   Shah, S ^b   Gulati, A ^a  

^a MIDWESTERN UNIVERSITY   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; Cerebral ischemia; GLP 1 receptor; Liraglutide; Oxidative stress

Indexed keywords

LIRAGLUTIDE; PROTEIN BAX; PROTEIN BCL 2; STREPTOZOCIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIAPOPTOTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CELL; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR PERFORMANCE; NEUROPROTECTION; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; TREATMENT DURATION; AGONISTS; ANIMAL; CEREBRAL ARTERY DISEASE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM;

ANIMALS; APOPTOSIS; BRAIN ISCHEMIA; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; LIRAGLUTIDE; MALE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84908377065     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.09.064     Document Type: Article

References (79)

1. Bake S., Selvamani A., Cherry J., Sohrabji F. Blood brain barrier and neuroinflammation are critical targets of IGF-1-mediated neuroprotection in stroke for middle-aged female rats. PloS one 2014, 9:e91427.
2. Banks W.A., During M.J., Niehoff M.L. Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther 2004, 309:469-475.
3. Barone F.C. Ischemic stroke intervention requires mixed cellular protection of the penumbra. Curr Opin Invest Drugs 2009, 10:220-223.
4. Bell G.I., Sanchez-Pescador R., Laybourn P.J., Najarian R.C. Exon duplication and divergence in the human preproglucagon gene. Nature 1983, 304:368-371.
5. Briyal S., Gulati K., Gulati A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res 2012, 1427:23-34.
6. Broughton B.R., Reutens D.C., Sobey C.G. Apoptotic mechanisms after cerebral ischemia. Stroke 2009, 40:e331-339.
7. Buteau J., El-Assaad W., Rhodes C.J., Rosenberg L., Joly E., Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004, 47:806-815.
8. Buteau J., Roduit R., Susini S., Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999, 42:856-864.
9. Chan P.H. Role of oxidants in ischemic brain damage. Stroke 1996, 27:1124-1129.
10. Chan P.H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cerebral Blood Flow Metab 2001, 21:2-14.
11. Choi D.W. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol 1996, 6:667-672.
12. Darsalia V., Mansouri S., Ortsater H., Olverling A., Nozadze N., Kappe C., Iverfeldt K., Tracy L.M., Grankvist N., Sjoholm A., Patrone C. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci 2012, 122:473-483.
13. Darsalia V., Ortsater H., Olverling A., Darlof E., Wolbert P., Nystrom T., Klein T., Sjoholm A., Patrone C. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes 2013, 62:1289-1296.
14. Dinkova-Kostova A.T., Talalay P. Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol Nutr Food Res 2008, 52(suppl. 1):S128-138.
15. Donnan G.A., Fisher M., Macleod M., Davis S.M. Stroke. Lancet 2008, 371:1612-1623.
16. Drucker D.J. Minireview: the glucagon-like peptides. Endocrinology 2001, 142:521-527.
17. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
18. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179.
19. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
20. Gengler S., McClean P.L., McCurtin R., Gault V.A., Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2012, 33:265-276.
21. Gisselsson L., Smith M.L., Siesjo B.K. Hyperglycemia and focal brain ischemia. J Cerebral Blood Flow Metab 1999, 19:288-297.
22. Gong G., Xiang L., Yuan L., Hu L., Wu W., Cai L., Yin L., Dong H. Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats. PloS one 2014, 9:e89450.
23. Gursoy-Ozdemir Y., Can A., Dalkara T. Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 2004, 35:1449-1453.
24. Hamilton A., Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009, 20:1161-1166.
25. Harkavyi A., Whitton P.S. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 2010, 159:495-501.
26. Holscher C. First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. Alzheimer's Dement 2014, 10:S33-S37.
27. Holscher C. The incretin hormones glucagon like peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimer's Dement 2014, 10:S47-54.
28. Hu X.L., Olsson T., Johansson I.M., Brannstrom T., Wester P. Dynamic changes of the anti- and pro-apoptotic proteins Bcl-w, Bcl-2, and Bax with Smac/Diablo mitochondrial release after photothrombotic ring stroke in rats. Eur J Neurosci 2004, 20:1177-1188.
29. Hui H., Nourparvar A., Zhao X., Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003, 144:1444-1455.
30. Hunter K., Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012, 13:33.
31. Husse B., Sopart A., Isenberg G. Cyclical mechanical stretch-induced apoptosis in myocytes from young rats but necrosis in myocytes from old rats. Am J Physiol Heart Circ Physiol 2003, 285:H1521-H1527.
32. Isacson R., Nielsen E., Dannaeus K., Bertilsson G., Patrone C., Zachrisson O., Wikstrom L. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 2011, 650:249-255.
33. Kakkar P., Das B., Viswanathan P.N. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys 1984, 21:130-132.
34. Kang H.M., Kang Y., Chun H.J., Jeong J.W., Park C. Evaluation of the in vitro and in vivo angiogenic effects of exendin-4. Biochem Biophys Res Commun 2013, 434:150-154.
35. Koizumi J., Yoshida Y., Nakazawa T., Ooneda G. Experimental studies of ischemic brain edema. 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke 1986, 8:1-8.
36. Lee C.H., Yan B., Yoo K.Y., Choi J.H., Kwon S.H., Her S., Sohn Y., Hwang I.K., Cho J.H., Kim Y.M., Won M.H. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res 2011, 89:1103-1113.
37. Lennox R., Porter D.W., Flatt P.R., Gault V.A. (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and beta-cell function in high-fat-fed mice. ChemMedChem 2013, 8:595-602.
38. Li F., Irie K., Anwer M.S., Fisher M. Delayed triphenyltetrazolium chloride staining remains useful for evaluating cerebral infarct volume in a rat stroke model. J Cereb Blood Flow Metab 1997, 17:1132-1135.
39. Li H., Lee C.H., Yoo K.Y., Choi J.H., Park O.K., Yan B.C., Byun K., Lee B., Hwang I.K., Won M.H. Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus. Neurosci Lett 2010, 486:38-42.
40. Li P.A., Gisselsson L., Keuker J., Vogel J., Smith M.L., Kuschinsky W., Siesjo B.K. Hyperglycemia-exaggerated ischemic brain damage following 30min of middle cerebral artery occlusion is not due to capillary obstruction. Brain Res 1998, 804:36-44.
41. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003, 278:471-478.
42. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
43. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
44. Luitse M.J., Biessels G.J., Rutten G.E., Kappelle L.J. Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol 2012, 11:261-271.
45. Ly J.V., Zavala J.A., Donnan G.A. Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke. Exp Opin Pharmacother 2006, 7:1571-1581.
46. Manzanero S., Santro T., Arumugam T.V. Neuronal oxidative stress in acute ischemic stroke: sources and contribution to cell injury. Neurochem Int 2013, 62:712-718.
47. Markgraf C.G., Green E.J., Hurwitz B.E., Morikawa E., Dietrich W.D., McCabe P.M., Ginsberg M.D., Schneiderman N. Sensorimotor and cognitive consequences of middle cerebral artery occlusion in rats. Brain Res 1992, 575:238-246.
48. Martinou J.C., Youle R.J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 2011, 21:92-101.
49. McClean P.L., Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 2014, 76(Pt A):57-67.
50. McClean P.L., Parthsarathy V., Faivre E., Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011, 31:6587-6594.
51. Megherbi S.E., Milan C., Minier D., Couvreur G., Osseby G.V., Tilling K., Di Carlo A., Inzitari D., Wolfe C.D., Moreau T., Giroud M., European BSoSCG Association between diabetes and stroke subtype on survival and functional outcome 3months after stroke: data from the European BIOMED Stroke Project. Stroke 2003, 34:688-694.
52. Mehta S.L., Manhas N., Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007, 54:34-66.
53. Micieli G., Marcheselli S., Tosi P.A. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vascular Health Risk Manag 2009, 5:397-409.
54. Moran P.M., Higgins L.S., Cordell B., Moser P.C. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proc Natl Acad Sci USA 1995, 92:5341-5345.
55. Nakka V.P., Gusain A., Mehta S.L., Raghubir R. Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities. Mol Neurobiol 2008, 37:7-38.
56. Niizuma K., Endo H., Chan P.H. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem 2009, 109(suppl. 1):133-138.
57. Niizuma K., Yoshioka H., Chen H., Kim G.S., Jung J.E., Katsu M., Okami N., Chan P.H. Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia. Biochim Biophys Acta 2010, 1802:92-99.
58. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
59. Parthsarathy V., Holscher C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PloS one 2013, 8:e58784.
60. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002, 302:881-888.
61. Perry T., Holloway H.W., Weerasuriya A., Mouton P.R., Duffy K., Mattison J.A., Greig N.H. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007, 203:293-301.
62. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002, 300:958-966.
63. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003, 72:603-612.
64. Reeves M.J., Vaidya R.S., Fonarow G.C., Liang L., Smith E.E., Matulonis R., Olson D.M., Schwamm L.H., Get With The Guidelines Steering C., Hospitals Quality of care and outcomes in patients with diabetes hospitalized with ischemic stroke: findings from Get With the Guidelines-Stroke. Stroke 2010, 41:e409-e417.
65. Rogers D.C., Campbell C.A., Stretton J.L., Mackay K.B. Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. Stroke 1997, 28:2060-2065. [discussion 2066].
66. Sato K., Kameda M., Yasuhara T., Agari T., Baba T., Wang F., Shinko A., Wakamori T., Toyoshima A., Takeuchi H., Sasaki T., Sasada S., Kondo A., Borlongan C.V., Matsumae M., Date I. Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci 2013, 14:21513-21524.
67. Sharma M.K., Jalewa J., Holscher C. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J Neurochem 2014, 128:459-471.
68. Stankowski J.N., Gupta R. Therapeutic targets for neuroprotection in acute ischemic stroke: lost in translation?. Antioxid Redox Signal 2011, 14:1841-1851.
69. Steculorum S.M., Solas M., Bruning J.C. The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. Alzheimer's Dement 2014, 10:S3-11.
70. Tatlisumak T., Carano R.A., Takano K., Opgenorth T.J., Sotak C.H., Fisher M. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: a diffusion and perfusion MRI study. Stroke 1998, 29:850-857. [discussion 857-8].
71. Taylor J.M., Crack P.J. Impact of oxidative stress on neuronal survival. Clin Exp Pharmacol Physiol 2004, 31:397-406.
72. Vela L., Gonzalo O., Naval J., Marzo I. Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation. J Biol Chem 2013, 288:4935-4946.
73. Vinik A., Flemmer M. Diabetes and macrovascular disease. J Diabetes Complications 2002, 16:235-245.
74. Wang X.H., Li L., Holscher C., Pan Y.F., Chen X.R., Qi J.S. Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 2010, 170:1239-1248.
75. Warner D.S., Sheng H., Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol 2004, 207:3221-3231.
76. Wohlfart P., Linz W., Hubschle T., Linz D., Huber J., Hess S., Crowther D., Werner U., Ruetten H. Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Transl Med 2013, 11:84.
77. Yang D., Nakajo Y., Iihara K., Kataoka H., Yanamoto H. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res 2013, 1517:104-113.
78. Yao H., Takasawa R., Fukuda K., Shiokawa D., Sadanaga-Akiyoshi F., Ibayashi S., Tanuma S., Uchimura H. DNA fragmentation in ischemic core and penumbra in focal cerebral ischemia in rats. Brain Res Mol Brain Res 2001, 91:112-118.
79. Yu Y.S., Sui H.S., Han Z.B., Li W., Luo M.J., Tan J.H. Apoptosis in granulosa cells during follicular atresia: relationship with steroids and insulin-like growth factors. Cell Res 2004, 14:341-346.